These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23114522)

  • 1. Product recall: a Croatian experience (2000-2010).
    Vuk T; Barišić M; Ljubičić J; Hećimović A; Juraković-Lončar N; Šarlija D; Jukić I
    Blood Transfus; 2013 Jul; 11(3):433-40. PubMed ID: 23114522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Error management in blood establishments: results of eight years of experience (2003-2010) at the Croatian Institute of Transfusion Medicine.
    Vuk T; Barišić M; Očić T; Mihaljević I; Sarlija D; Jukić I
    Blood Transfus; 2012 Jul; 10(3):311-20. PubMed ID: 22395352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of FDA drug recalls: A 30-month analysis.
    Hall K; Stewart T; Chang J; Freeman MK
    Am J Health Syst Pharm; 2016 Feb; 73(4):235-40. PubMed ID: 26843501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial contamination of blood products at the Croatian Institute of Transfusion Medicine: results of eleven-year monitoring.
    Vuk T; Barišić M; Hećimović A; Rukavina L; Batarilo I; Šarlija D; Jukić I
    Transfus Med; 2012 Dec; 22(6):432-9. PubMed ID: 23020303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Medicines Recall Announcements in Saudi Arabia Between 2017 and 2022: An Analysis of Saudi Food and Drug Authority (SFDA) Reports.
    Almutairi M; Algabbani A; Alasiri A; Alhomaidan A; Alqahtani AS
    Ther Innov Regul Sci; 2024 Jul; 58(4):689-695. PubMed ID: 38546962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Categorization and comparisons of drug recalls for manufacturers and compounders.
    Mattingly AN; Mattingly TJ; Nguyen Phan AL; Negash K
    J Am Pharm Assoc (2003); 2022; 62(4):1344-1350. PubMed ID: 35422393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood product recalls in the United States.
    McCullough J; Riley E; Lindgren B; Pulkrabek S; Hall R; Riley W
    Transfusion; 2014 Sep; 54(9):2276-82. PubMed ID: 24863173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of complaints in blood establishments: thirteen years of experience at the Croatian Institute of Transfusion Medicine.
    Vuk T; Barišić M; Očić T; Đogić V; Bingulac-Popović J; Sarlija D; Balija M; Jukić I
    Blood Transfus; 2012 Jul; 10(3):302-10. PubMed ID: 22507865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States.
    Alqemlas I; Shankar S; Handagama W; Felse PA
    Blood Adv; 2020 Apr; 4(8):1780-1791. PubMed ID: 32343797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood component recalls in the United States.
    Ramsey G; Sherman LA
    Transfusion; 1999 May; 39(5):473-8. PubMed ID: 10335996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The continuing challenge of drug recalls: Insights from a ten-year FDA data analysis.
    Ghijs S; Wynendaele E; De Spiegeleer B
    J Pharm Biomed Anal; 2024 Oct; 249():116349. PubMed ID: 39029352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trends in Non-prescription Drug Recalls in Japan].
    Yamamoto C; Ishida T; Osawa T; Naito T; Kawakami J
    Yakugaku Zasshi; 2016; 136(9):1307-12. PubMed ID: 27592833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A four-year assessment of the characteristics of Rwandan FDA drug recalls.
    Bahizi M; Nyirimigabo E; Ntirenganya L; Umuhoza MI; Habyalimana V; Bikorimana G; Ukwishaka J
    BMC Public Health; 2024 Jul; 24(1):1784. PubMed ID: 38965502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of Medicines in Portugal: A Retrospective Review of Medicine Recalls (2000-2015).
    Machado Reis AT; Berardo BFR; Loureiro R
    PDA J Pharm Sci Technol; 2018; 72(1):44-49. PubMed ID: 29030530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
    Bharate SS
    J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total recall. Providers are taking the lead in revamping system for handling questionable drugs and medical devices.
    Lee J
    Mod Healthc; 2011 Aug; 41(32):28, 30. PubMed ID: 21879697
    [No Abstract]   [Full Text] [Related]  

  • 18. Nitrosamine Impurities in Angiotensin Receptor Blockers.
    Shephard EA; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nature and pattern of coronary stent recalls.
    Kumar S; Innasimuthu AL; Marmur JD
    J Invasive Cardiol; 2014 Sep; 26(9):433-6. PubMed ID: 25198486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of implantable cardioverter-defibrillator recalls on patients' anxiety, depression, and quality of life.
    Undavia M; Goldstein NE; Cohen P; Sinthawanarong K; Singson M; Bhutani D; Munson T; Gomes JA; Fischer A; Mehta D
    Pacing Clin Electrophysiol; 2008 Nov; 31(11):1411-8. PubMed ID: 18950298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.